-
Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio
•
Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo’s Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao. Deal DetailsThe…
-
PerkinElmer and SCUT Launch Joint Translational Medicine Center
•
US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint translational medicine center of excellence. The center, located at SCUT’s Medical College in Guangzhou, Guangdong, is equipped with advanced scientific research tools from PerkinElmer and is open to the public. Center DetailsThe laboratory features cutting-edge…
-
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its CMAB015, a biosimilar of Novartis’ Cosentyx (secukinumab). The study will target psoriasis and ankylosing spondylitis. Drug ProfileCosentyx was first approved…
-
CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co., Ltd, has entered into a licensing agreement with US-based Elevation Oncology Inc. (NASDAQ: ELEV). The deal grants Elevation exclusive development and commercialization rights to CSPC Jushi’s Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) candidate SYSA1801…
-
Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing
•
Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR) T-cell therapies, making it the first company in Beijing and one of a few nationally to receive the certification as a gene therapy firm. Approval SignificanceThe license confirms that Immunochina’s facilities comply with quality regulations,…
-
Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System
•
Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer) chip technology, has raised nearly RMB 100 million (USD 14.8 million) in a Series B2 financing round. The round was led by Qianrong Investment and included participation from Walden International. Funding UseProceeds from the funding…
-
Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su
•
Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product specifically designed for cancer patients. Branded as Oral Impact Su Yi Su, the product provides a non-inflammatory diet for individuals recovering from cancer treatment, containing arginine, fish oil, omega-3, and nucleotides in addition to standard…
-
Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy
•
Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online hospital sector to advance the company’s digital health strategies, despite regulatory hurdles and profitability challenges. Regulatory LandscapeHornstein, who will soon take over as Sanofi’s global digital division head, addressed new rules issued in March 2022…
-
Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)
•
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in a Phase I clinical study for its ketorolac for IV infusion (NTM-001), a non-opioid analgesic co-developed with US-based Neumentum Inc. Study DetailsThe Phase I study enrolled 16 healthy subjects, who have completed the 96-hour sample…
-
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has accepted a supplementary Biologic License Application (sBLA) for its HanBeiTai, a biosimilar of Roche’s Avastin (bevacizumab), for review. The application is intended for the treatment of recurrent glioblastoma (GBM). Drug ProfileHanBeiTai was first approved in…
-
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
•
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG: 9960) to advance precision diagnosis and treatment in blood tumors. The partnership aims to enhance educational activities, promote the concept of precision detection and treatment, and improve the accessibility and standardization of genetic testing for…
-
Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal
•
China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun Pharmaceutical Group Ltd (HKG: 1681) to acquire 238,056,948 shares at RMB 9.17 (USD 1.36) per share, valuing the transaction at approximately RMB 2.2 billion (USD 325 million). About Consun PharmaceuticalConsun Pharma, listed on the Hong…
-
Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1
•
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab has demonstrated sustained neutralizing activity against the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. Study ResultsLive virus neutralization experiments conducted in the US showed that 14 days after dosing, the total plasma concentration of the combination…
-
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
•
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY Biopharma Co., Ltd, securing global rights to the latter’s tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) for intravitreal injection. Financial terms were not disclosed. Agreement DetailsThe deal encompasses…
-
HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
•
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic…
-
Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing
•
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic partnership on July 24, with the inauguration of the “Roche Diagnostics-Topgen Innovation Center of Excellence” in Chongqing. Center OverviewThe innovation center comprises several key facilities:
-
Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer agreement with the National Institute for Viral Disease Control and Prevention, China’s CDC. The deal grants Hybio licensed use of technical secrets related to peptide sequences for vaccine development. Agreement DetailsHybio will pay an upfront…
-
Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development
•
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a three-year partnership with Huawei Technologies Co., Ltd to explore the application of artificial intelligence (AI) in drug development. The collaboration will focus on macro and small molecule drug design, related diseases, and database development. Partnership…
-
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration (NMPA) has accepted a market filing from its non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd for a combination therapy of fulvestrant and piroxetine in advanced breast cancer. This marks Xuanzhu Bio’s first filing for an…
-
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme Corp. (MSD) has entered into a second licensing agreement, securing global development, manufacturing, and commercialization rights to an undisclosed investigational antibody drug conjugate (ADC) from Kelun’s pipeline. The deal includes an upfront payment of USD…
